{"organizations": [], "uuid": "1e25beacdb69c5dac2d12ac4ec60457a3af937a0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/6", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/01/globe-newswire-progenics-pharmaceuticals-sets-fourth-quarter-and-year-end-2017-financial-results-call-for-march-8.html", "country": "US", "domain_rank": 767, "title": "Progenics Pharmaceuticals Sets Fourth Quarter Year-End Financial Call for March 8", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.034, "site_type": "news", "published": "2018-03-01T16:00:00.000+02:00", "replies_count": 0, "uuid": "1e25beacdb69c5dac2d12ac4ec60457a3af937a0"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/01/globe-newswire-progenics-pharmaceuticals-sets-fourth-quarter-and-year-end-2017-financial-results-call-for-march-8.html", "ord_in_thread": 0, "title": "Progenics Pharmaceuticals Sets Fourth Quarter Year-End Financial Call for March 8", "locations": [], "entities": {"persons": [], "locations": [{"name": "new york", "sentiment": "none"}], "organizations": [{"name": "progenics pharmaceuticals", "sentiment": "negative"}, {"name": "progenics pharmaceuticals, inc.", "sentiment": "neutral"}, {"name": "progenics", "sentiment": "none"}, {"name": "progenics progenics", "sentiment": "none"}, {"name": "media center", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "NEW YORK, March 01, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, announced today that it will host a conference call and webcast to review the fourth quarter and year ended December 31, 2017 financial results on Thursday, March 8, 2018, at 8:30 a.m. ET.\nTo participate, please dial (877) 250-8889 (domestic) or (720) 545-0001 (international) and reference conference ID 4085568. A live webcast will be available in the Media Center of the Progenics website, www.progenics.com, and a replay will be available for two weeks.\nAbout Progenics\nProgenics develops innovative medicines and other technologies to target and treat cancer. Progenics' pipeline includes: 1) therapeutic agents designed to precisely target cancer (AZEDRA ® and 1095), 2) PSMA-targeted imaging agents for prostate cancer (1404 and PyL™), and 3) imaging analysis technology. Progenics' first commercial product, RELISTOR ® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with Valeant Pharmaceuticals International, Inc.\nThis press release may contain projections and other \"forward-looking statements\" regarding future events. Statements contained in this communication that refer to Progenics' estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Progenics' current perspective of existing trends and information as of the date of this communication. Forward looking statements generally will be accompanied by words such as \"anticipate,\" \"believe,\" \"plan,\" \"could,\" \"should,\" \"estimate,\" \"expect,\" \"forecast,\" \"outlook,\" \"guidance,\" \"intend,\" \"may,\" \"might,\" \"will,\" \"possible,\" \"potential,\" \"predict,\" \"project,\" or other similar words, phrases or expressions. Such statements are predictions only, and are subject to risks and uncertainties that could cause actual events or results to differ materially. These risks and uncertainties include, among others, the cost, timing and unpredictability of results of clinical trials and other development activities and collaborations, such as the Phase 3 clinical program for 1404; our ability to successfully develop and commercialize the products of EXINI Diagnostics AB; the unpredictability of the duration and results of regulatory review of New Drug Applications (NDA) and Investigational NDAs, including our NDA for AZEDRA and related inspections of Progenics’ and its contract manufacturing organizations’ facilities and other sites and other requirements that will need to be met before any approval is obtained; market acceptance for approved products; the effectiveness of the efforts of our partners to market and sell products on which we collaborate and the royalty revenue generated thereby; generic and other competition; the possible impairment of, inability to obtain and costs of obtaining intellectual property rights; possible product safety or efficacy concerns, general business, financial, regulatory and accounting matters, litigation and other risks. More information concerning Progenics and such risks and uncertainties is available on its website, and in its press releases and reports it files with the U.S. Securities and Exchange Commission, including those risk factors included in its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2017, as updated in its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2017. Progenics is providing the information in this press release as of its date and, except as expressly required by law, Progenics disclaims any intent or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances or otherwise.\nAdditional information concerning Progenics and its business may be available in press releases or other public announcements and public filings made after this release. For more information, please visit www.progenics.com . Information on or accessed through our website or social media sites is not included in the company's SEC filings.\n(PGNX-F)\nContact :\nMelissa Downs\nInvestor Relations\n(646) 975-2533\nmdowns@progenics.com\nSource:Progenics Pharmaceuticals Inc.", "external_links": ["https://www.globenewswire.com/NewsRoom/AttachmentNg/23fd2682-25c5-435e-9ecf-6a3079ca6226", "https://www.globenewswire.com/Tracker?data=uqQ-VOY6g0hwXFNGAtM6Ey0vVqygTBK7rU9cCxSInMYRSvia26mJGhA11kHnNo1PFpM-oTGEeB_mg5uJ-aDWug=="], "published": "2018-03-01T16:00:00.000+02:00", "crawled": "2018-03-01T17:36:33.006+02:00", "highlightTitle": ""}